Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shobha Swaminathan

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
The Journal of Infectious Diseases|May 10, 2022
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) TrialHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 15, 2023
Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency VirusScott L Letendre, Huichao Chen, Ashley McKhann, et al.
The Journal of Infectious Diseases|August 13, 2021
Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort StudyDaniel B Horton, Emily S Barrett, Jason Roy, et al.
Open Forum Infectious Diseases|October 27, 2025
Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2--LTR Circles Over 12 WeeksJonathan C Reed, Luke Hall, Ashley McKhann, et al.
Journal of Clinical Microbiology|May 6, 2020
Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 TestMichael J Loeffelholz, David Alland, Susan M Butler-Wu, et al.
Emerging Infectious Diseases|January 25, 2024
Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021Jessica Justman, Timothy Skalland, Ayana Moore, et al.
Annals of Internal Medicine|August 23, 2017
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized TrialRoy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2026
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 StudyRaphael J Landovitz, Yvett Pinedo, Federico Hinestrosa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2020
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of CareSusan A Olender, Katherine K Perez, Alan S Go, et al.
The New England Journal of Medicine|August 11, 2021
Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J Landovitz, Deborah Donnell, Meredith E Clement, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
The Journal of Infectious Diseases|May 10, 2022
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) TrialHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 15, 2023
Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency VirusScott L Letendre, Huichao Chen, Ashley McKhann, et al.
The Journal of Infectious Diseases|August 13, 2021
Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort StudyDaniel B Horton, Emily S Barrett, Jason Roy, et al.
Open Forum Infectious Diseases|October 27, 2025
Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2--LTR Circles Over 12 WeeksJonathan C Reed, Luke Hall, Ashley McKhann, et al.
Journal of Clinical Microbiology|May 6, 2020
Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 TestMichael J Loeffelholz, David Alland, Susan M Butler-Wu, et al.
Emerging Infectious Diseases|January 25, 2024
Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021Jessica Justman, Timothy Skalland, Ayana Moore, et al.
Annals of Internal Medicine|August 23, 2017
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized TrialRoy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2026
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 StudyRaphael J Landovitz, Yvett Pinedo, Federico Hinestrosa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 25, 2020
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of CareSusan A Olender, Katherine K Perez, Alan S Go, et al.
The New England Journal of Medicine|August 11, 2021
Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J Landovitz, Deborah Donnell, Meredith E Clement, et al.
Pageof 4